In the last trading session, 1.57 million Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) shares changed hands as the company’s beta touched 1.48. With the company’s per share price at $15.15 changed hands at $0.37 or 2.50% during last session, the market valuation stood at $504.34M. ICPT’s last price was a discount, traded about -197.49% off its 52-week high of $45.07. The share price had its 52-week low at $11.60, which suggests the last value was 23.43% up since then. When we look at Intercept Pharmaceuticals Inc.’s average trading volume, we note the 3-month average coming to 835.07K.
Analysts gave the Intercept Pharmaceuticals Inc. (ICPT) stock a consensus recommendation rating of a Hold, calculated at a mean rating of 2.70. If we narrow down to specifics, the data shows that 1 out of 19 analysts rate the stock as a Sell, with a further 2 assigning it an Overweight rating. Of the remaining, 12 recommended ICPT as a Hold, 3 felt it is a Buy and 1 rated the stock as Underweight. Intercept Pharmaceuticals Inc.’s EPS for the current quarter is expected to be -$1.12.
Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) trade information
Instantly ICPT was in green as seen at the end of in last trading. With action 5.21%, the performance over the past five days has been green. The jump to weekly highs of 15.29 on Tuesday, 09/14/21 added 2.50% to the stock’s daily price. The company’s shares are showing year-to-date downside of -38.66%, with the 5-day performance at 5.21% in the green. However, in the 30-day time frame, Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) is 1.54% up.
The consensus price target for the stock as assigned by Wall Street analysts is $31.28, meaning bulls need an upside of 51.57% from its current market value. According to analyst projections, ICPT’s forecast low is $10.00 with $82.00 as the target high. To hit the forecast high, the stock’s price needs a -441.25% plunge from its current level, while the stock would need to tank 33.99% for it to hit the projected low.
Intercept Pharmaceuticals Inc. (ICPT) estimates and forecasts
Data shows that the Intercept Pharmaceuticals Inc. share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -34.19% over the past 6 months, a 53.60% in annual growth rate that is considerably higher than the industry average of 7.40%. Moreover, analysts have looked to higher expectations by upgrading its fiscal year 2021 revenue estimates. The rating firms predict current quarter revenue for Intercept Pharmaceuticals Inc. will rise 44.30%, while the growth in revenue is estimated to hit 10.10% for the next quarter. Year-over-year growth is forecast to reach 8.00% up from the last financial year.
Consensus estimates given by 19 financial analysts project the company’s revenue in the current quarter to hit an average of $81.81 million. 19 analysts are of the opinion that Intercept Pharmaceuticals Inc.’s revenue for the quarter ending Dec 2021 will be $79.1 million. The estimates for the next quarter sales put growth at -5.00%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 2.70%. The 2021 estimates are for Intercept Pharmaceuticals Inc. earnings to increase by 23.40%, but the outlook for the next 5-year period is at -8.89% per year.
Intercept Pharmaceuticals Inc. is expected to release its next quarterly earnings report between November 08 and November 12.
Intercept Pharmaceuticals Inc. (NASDAQ:ICPT)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 15.45% of Intercept Pharmaceuticals Inc. shares while 69.18% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 81.82%. There are 69.18% institutions holding the Intercept Pharmaceuticals Inc. stock share, with Vanguard Group, Inc. (The) the top institutional holder. As of Jun 29, 2021, the company held 10.16% of the shares, roughly 3.37 million ICPT shares worth $67.36 million.
State Street Corporation holds the second largest percentage of outstanding shares, with 8.00% or 2.66 million shares worth $53.05 million as of Jun 29, 2021.
Among Mutual Funds, the top two as of Jun 29, 2021 were SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF and Fidelity Series Large Cap Stock Fund. With 2.13 million shares estimated at $42.58 million under it, the former controlled 6.42% of total outstanding shares. On the other hand, Fidelity Series Large Cap Stock Fund held about 2.95% of the shares, roughly 0.98 million shares worth around $16.93 million.